Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFC14A
Source: 0001193125-25-086293
Chunk: 58

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFC14A
Chunk 58
---
, and our restricted stock units vest in equal annual installments over a period of three years, subject to continued service. However, our Compensation Committee may, from time to time, construct alternate vesting schedules as it determines are appropriate to motivate particular employees. Additionally, stock options and restricted stock units granted to our employees may be subject to accelerated vesting in certain circumstances, as described below in the section titled “Employment Arrangements and Potential Payments upon Termination of Employment.” For employees who are not officers of the Company, we generally award stock options and restricted stock units on the date the single-member non-officerstock 57

award subcommittee of the Compensation Committee (the “Option Committee”) approves the grant. In 2015, the Compensation Committee formed this Option Committee, currently composed of our Chief Executive Officer, to which it delegated authority to grant, without any further action required by the Compensation Committee, stock awards to employees who are not officers of the Company, provided that such grants are made in accordance with guidelines established by the Compensation Committee. If employees are officers of the Company, we award stock options and restricted stock units on the date the Compensation Committee approves the grant. We set the option exercise price as the last reported sale price of our common stock on the Nasdaq Stock Market on the date of grant. We awarded stock options and restricted stock units to our NEOs during 2024 in the following amounts and with the vesting schedules indicated below. These options were granted with exercise prices equal to the fair market value of our common stock on the date of grant, as determined by our Compensation Committee.

| Name                         |     | Number of Shares Subject to 
         Options Granted (1) |     | Number ofRSUs Granted (2) |
| Neil F. McFarlane            |     |                           - |     |                   700,000 |
| Adrian Quartel, M.D., FFPM   |     |                     300,000 |     |                         - |
| R. LaDuane Clifton, MBA, CPA |     |                           - |     |                   130,000 |

| (1) | The option award vests in equal annual installments over a period of four years, subject to continued service. Additionally, the option award will vest in full and become immediately exercisable upon a change of control of the Company or if the executive is terminated without cause or resigns for good reason (each as defined in the executive’s employment agreement, discussed under the section entitled “Employment Arrangements